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Chairman’s Report
Every week during the last year, people have been facing unimaginable circumstances surrounding the downturn in
the economy. People have lost their jobs, lost eligibility for health coverage, exhausted savings and prematurely tapped
into retirement savings. Imagine facing these issues along with a new diagnosis of cancer. It happens frequently
and is a major challenge for patients and our comprehensive community cancer program.
Medical costs for cancer treatment in the United States are high and continue to increase. The cost of medical care for
a cancer diagnosis has nearly doubled since the mid 1980s. Treatment options have become more complex and costly
but have resulted in more patients surviving this disease. With an aging population and improved screening, diagnosis
and treatment options, the number of people with cancer has more than doubled; it now affects about 27.8 million
people with the corresponding cancer expenditures reaching $979 billion.
In calendar year 2009, St. Cloud Hospital entered 1,561 new cancer cases into its registry (representing cancers
diagnosed and/or patients receiving treatment at St. Cloud Hospital, Coborn Cancer Center and CentraCare Radiation
Oncology at Douglas County Hospital). Since 1994, more than
18,800 patients have received their cancer care here. We recognize
that these numbers reflect patient confidence in the diagnostic and
treatment capabilities of our physicians and St. Cloud Hospital.
Having the available technology, drugs, physicians and staff, while
critically important, is not all that is needed to support a patient
and his/her family through diagnosis and treatment. During these
tough economic times, addressing the financial challenges facing
patients has become a key priority for our cancer program. We
have worked hard to improve clinical services, assure available
technology, add physician specialists and advance quality initiatives
to enable optimal outcomes for our patients.
We are equally proud of our efforts during the last year to provide
more comprehensive survivorship support services to patients at
no cost. While many cancer programs across the United States have been forced to cut back or omit support programs,
we have been able to expand these services with support from St. Cloud Hospital and CentraCare Health Foundation.
Program enhancements include:
• Oncology social workers who are available for inpatients at St. Cloud Hospital and outpatients at Coborn Cancer
Center. Coborn Cancer Center’s social worker has completed special certification to work with patients having
financial concerns, an ever-growing need for our patients.
• Dedicated Coborn Cancer Center staff who assist patients to optimize available insurance benefits. These staff
members also act as liaisons with pharmaceutical-sponsored assistance programs to obtain low or no-cost drugs
based on patients’ financial situations.
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Achievements
• Additional disease site registered nurse care coordinators. There are now
three highly specialized coordinators available to work with patients, primary
care providers, oncologists and other specialists regarding breast, lung and
gastrointestinal (stomach, colorectal, esophagus, liver and pancreas) cancers.
The care coordinator may enter a patient’s life when a cancer is first suspected
or newly diagnosed. These specialized nurses are health care partners who help
with questions, education and support throughout the cancer journey.
• A transportation assistant, available to meet patients and families at the door
of Coborn Cancer Center and provide a wheelchair or an extra pair of hands
when needed.
• Expert cancer-focused registered dietitians. These professionals provide
nutritional assessment and support to help patients and their families maintain
weight and nutrition. This improves the likelihood that they will complete
treatment and thus improve overall outcomes and quality of life.
• Access to a free educational program entitled “Tools for Making Health Care
Decisions.” This program uses evidence-based tools to teach community
members proactive decision support skills which can be helpful when faced
with a tough health care decision.

Coborn Cancer Center is proud
to be a department of St. Cloud
Hospital and is equally proud
to provide the same high-quality
care that St. Cloud Hospital is
known for.
St. Cloud Hospital’s national
recognition includes:
• Magnet Award for Excellence
in Nursing (2004-2008,
2009-2013)
• Thomson Reuters Top 100
Hospital (1993, 1994, 1999,
2005-2009)
• An “America’s Best Hospital”
U.S. News & World Report
(2005-2009)

• Emotional support for children through the CLIMB® (Children’s
Lives Include Moments of Bravery) program. Specially trained
facilitators provide ongoing sessions for children who have
a parent or primary caregiver with cancer.
• Support groups for many cancer diagnoses, art therapy and
other events sponsored by Coborn Cancer Center and several
other community care providers. All are well-received and free
to participants.
Even in the face of health care reform and the ever-changing
landscape of oncology, we continue to strive to be a leader for
quality, safety, service and value. We thank you for trusting us
with your life and health.
Twilight at Coborn Cancer Center at the CentraCare Health Plaza.

Jo Zwilling, RN, MBA
Cancer Program Director

Nicholas F. Reuter, MD, FACP
Cancer Medical Director
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Life hits high note after cancer experience
Kirsten Hoese had a love for music
during her teen and college years —
but never had the time to pursue it.
Life got busy with work, raising a
family and then helping care for her
grandson, Brock. So, ovarian cancer
came as a startling diagnosis when
she was 62. “It hit me hard — it
just came out of the blue,” she said.
“At first I was scared. I didn’t think
I’d make it a year.”
Thankfully for Kirsten, Coborn
Cancer Center offered intraperitoneal
chemotherapy*, for which she was
a perfect candidate. She credits her
recovery to staying busy, reading,
exercising, a healthy diet and caring
for her grandson. “I wanted to be
there for him,” she said.
After facing the music with cancer,
today, Kirsten has struck a chord
with her passion. She started taking
voice lessons and enjoys her time
with Brock. “I appreciate it all so
much more . . . you have to make
the most of every day!”

Kirsten Hoese, Elk River,
ovarian cancer survivor
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* Intraperitoneal (IP) chemotherapy is a
widely used treatment for ovarian cancer.
It delivers anti-cancer drugs directly into
the abdomen through a tube in a more
targeted approach than traditional
chemotherapy. The treatment requires
the expertise of a handful of various
specialties. There are a relatively small
number of ovarian cancer patients in
our area, however, given the diverse
medical specialties in the community
and our commitment to offering
cutting-edge treatments, we are able
to offer IP chemotherapy to those who
are candidates.

On the green, with a bigger smile
After two of her sisters were diagnosed with breast cancer, Janna Cannon, age 57 of Sauk Rapids, decided not to
put off her mammogram. Ten days later, she too, was diagnosed with breast cancer. All three sisters’ diagnoses came
within 15 short months.
“I wasn’t going to have reconstructive
surgery.” Janna said. But after
exploring the possibility with her
surgeon, John Houle, MD, Midsota
Plastic Surgeons, she didn’t have
a second thought about having
a Deep Inferior Epigastric Artery
Perforator (DIEP) flap procedure.*
“It was a positive, life-changing
experience,” Janna said. “It gave me
hope — after being taken apart and
put back together — of being not
only the same me, but a better me.”
Today, Janna spends her free time
with family or on the golf course.
After going through her cancer
experience Janna says “It’s a
better me, with a bigger smile!”

Janna Cannon, Sauk Rapids,
breast cancer survivor

* The “Deep Inferior Epigastric Artery
Perforator” (DIEP) flap is a breast
reconstruction procedure. DIEP flap is
the latest and most technically advanced
procedure for reconstructing a patient’s
breast using her own tissue from the
abdomen. DIEP flap may cause less pain,
allow for a shorter hospitalization
and decrease the chances of some
complications.
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Hockey games and mammograms . . .
too important to miss
Shannon Petroske, St. Cloud,
breast cancer survivor

Shannon Petroske, mother of three had it all, a loving family, an active life with her job and kids’ activities . . . and a
family history of breast cancer. She always did self breast exams but followed her doctor’s advice to start mammograms
at age 38. And thankfully so. The following year, Shannon was diagnosed with breast cancer.
“I’m so glad I talked to my doctor when I did,” she said. “Had I waited until 40, I fear I would not be where I am today.”
Between hockey, soccer and dance practice, Shannon makes sure never to miss important appointments.
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Journey with cancer can’t trump travels
Judy Scheuerell has traveled to exotic locations such as India and Russia. But in 2007, her love of travel led to a foreign
journey — a journey with breast cancer.
When Judy, 68, had her annual
mammogram, they found a lump in
her left breast. She had early-stage
breast cancer.
Judy was treated at the Coborn
Cancer Center in St. Cloud and
was fortunate enough to be a
candidate for MammoSite® 5-Day
Targeted Radiation Therapy.*
“MammoSite therapy got me
through my radiation treatment in
less than a week and back to my
normal, active life again,” Judy said.
“The day that I went in for my
mammogram to the end of
MammoSite therapy took less than
one month. And, I only had mild
fatigue and discomfort.
It was amazing.”
Judy has returned to
her everyday life and
continues to do all
the things she loves:
play golf, tennis,
bridge, ski, read and
especially travel.

Judy Scheuerell, Sartell,
breast cancer survivor

* MammoSite® is a breast conservation
therapy that delivers radiation in the
space left when the tumor is surgically
removed. MammoSite may be an option
for patients with early-stage breast cancer,
who are candidates for a lumpectomy
and meet certain other criteria. A benefit
of the therapy is the shortened radiation
procedure time — five days total versus
the traditional 35 days.
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A focus on Women’s Cancers

Breast Cancer
Incidence
In 2009, there were 306 female breast cancer
cases diagnosed and/or treated at St. Cloud
Hospital. This compares to 258 women in
2008. Although the national incidence of
breast cancer has decreased about 2% per
year from 1999-2006, the numbers diagnosed
and/or treated by St. Cloud Hospital continue
to increase. This is likely due to increasing
population growth in the service area and
availability of comprehensive breast services
located at St. Cloud Hospital rather than
increased incidence.

Cancers that occur primarily in women include breast, uterine
and ovarian. In the United States, these three cancers accounted
for 36% of the new cancers diagnosed in women during 2009.
There were 785 women newly diagnosed with cancer during
2009 at St. Cloud Hospital. Breast, uterine and ovarian cancers
accounted for 45% of these cases.
For this annual report, Maria Mallory, MD, and Christian Schmidt,
MD, surgeons with CentraCare Clinic – River Campus, were asked
to take a close look at breast cancer care at St. Cloud Hospital.
Robert Stocker, MD, gynecologist with CentraCare Clinic —
Women & Children and Nathaniel Reuter, MD, surgical oncologist
with CentraCare Clinic – River Campus, took a further look into
ovarian and endometrial cancers. The following focus studies are a
summary of their findings and the impact on St. Cloud Hospital and
the community.

Screening

Stage at diagnosis
The majority of breast cancer cases diagnosed at
St. Cloud Hospital are considered early stage (0-1)
using the American Joint Committee on Cancer
(AJCC) staging system. As seen in Table 1, these cases
8 | Cancer Report 2009

% OF CASES

According to the Centers for Disease Control (CDC), 81% of women,
ages 50-74, received the recommended mammography screening for
breast cancer in 2008. Combining data from 2002-2006, the percent
Maria Mallory, MD
Christian Schmidt, MD
of women, ages 40 and older, who reported having a mammogram in
the previous two years was somewhat lower, in rural areas (78%) than
urban areas (82%) in Minnesota. New controversial breast cancer screening recommendations from the United States
Preventative Services Task Force (USPSTF) were published in 2009. Women, ages 40-49, were recommended to
not have an annual mammogram and women, ages 50-75, were only to be screened every two years instead
of annually. These new recommendations resulted
TABLE 1
in confusion and controversy. At this time, most
health care providers continue to follow the
Breast Cancer: AJCC Stage at Diagnosis
more conservative recommendations by the
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB)
American Cancer Society — to begin mammography
50%
screening at age 40 and to continue annually
regardless of age unless the woman has
40%
serious chronic health problems and a limited
30%
life expectancy.
20%
10%
0%

0

I

II

III

IV

Unknown

SCH 2007-2009

17%

40%

25%

10%

4%

3%

MN NCDB 2007

21%

40%

24%

9%

3%

2%

Nat’l NCDB 2007

19%

37%

24%

9%

3%

7%

©2010 National Cancer Data Base, Commission on Cancer

TABLE 2

Breast Conserving Surgery vs Mastectomy
AJCC Stage I and II Cases
St. Cloud Hospital* (SCH) and National Cancer Data Base (NCDB)
80%

% OF CASES

accounted for 57% of the total breast cancer cases seen at St. Cloud
Hospital. The hospital’s breakdown by stage is comparable to
Minnesota and national rates as reported by the National Cancer
Data Base (NCDB). Today, most women are diagnosed by ultrasound
or stereotactic needle biopsy as an outpatient procedure in contrast
to open surgical biopsy done in the past. Early diagnosis for women
diagnosed with breast cancer at St. Cloud Hospital is attributed to
focused emphasis on screening by providers and women themselves.

Treatment

60%
40%

56%
44%

54%

63%
46%

37%

20%
0%

SCH: 2007 to 2009
MN NCDB 2007
Nat’l NCDB 2007
A diagnosis of early stage breast cancer offers a variety of treatment
Breast
Conserving
Surgery
Mastectomy
options beginning with surgery — mastectomy versus breast conserving
surgery. Research shows women with early stage breast cancer
* SCH Cases: Only patients receiving surgery at St. Cloud Hospital
treated with breast conserving surgery plus radiation therapy were
©2010 National Cancer Data Base, Commission on Cancer
as likely to be alive and disease-free 20 years later as women treated
with mastectomy. Fifty-six percent of women with stage I-II breast cancer treated surgically at St. Cloud Hospital had
breast conserving surgery. This compares well with Minnesota and national statistics (Table 2).

An important national measure of quality is radiation therapy administered within one year of diagnosis for women under
age 70 who received breast conserving surgery. Even when considering two patients who declined the recommended radiation,
St. Cloud Hospital had 99% of patients receiving the recommended radiation therapy.
Women are referred for cancer risk assessment and genetic counseling when their
personal or family history is suggestive of familial or hereditary cancer. This is
another important step in the follow-up treatment for women with breast cancer.

Survival
With a 91% overall five-year survival rate for breast cancer, St. Cloud Hospital
compares favorably to Minnesota and national rates (Table 3). When considering
long-term survival rates, the rates reflect women treated using past therapies and
may not reflect more recent advances in early detection or treatment.

Summary

TABLE 3

Breast Cancer: Five Year Observed Survival Rates
All Stages: 1998 to 2002
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB)

CUMULATIVE
SURVIVAL RATE

100%
80%

91%

89%

85%

60%
40%
20%
0%

SCH

MN NCDB

©2010 National Cancer Data Base, Commission on Cancer

Nat’l NCDB

The Breast Center extends its services
and expert care to women across
Central Minnesota with its Mobile
Mammography Program. A fully
equipped vehicle visits more than
a dozen communities.

Breast care continues
to evolve. Awareness
and screening programs
have lead to earlier
In 2009, the mobile program screened
diagnosis. A multi2,458 women, including 114 done at
disciplinary approach
reduced or no cost through SAGE,
has become the
Minnesota’s cancer screening program.
standard of care. A new
weekly breast cancer
conference has been
developed to review new breast cancers and treatment
options. This is one example of our commitment to
state-of-the-art care.
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Uterine (Endometrial)
Cancer
Incidence
Endometrial cancer starts in the lining of the uterus. It is the most common type of uterine
cancer and accounts for approximately 6% of the new cancers diagnosed in women each
year in the United States. The American Cancer Society estimates that more than 43,000
cases will be diagnosed in 2010 across the country. There were 31 patients diagnosed
and/or treated for endometrial cancer at St. Cloud Hospital during 2009. This represented
4% of the newly diagnosed cancers in women seen at the hospital during that year.

Robert Stocker, MD

Screening

% OF CASES

Although the cause of endometrial cancer is unknown, increased estrogen levels appear to play a role. There is
no standard or routine screening test for endometrial cancer, however, all women should have a pap/pelvic exam
routinely. If a woman is determined to be at high risk by her physician, screening annually with endometrial biopsy
and/or transvaginal ultrasound,
TABLE 4
beginning at age 35, may be
recommended. If a woman after
Endometrial Cancer: Age at Diagnosis
age 40 experiences a change in
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB)
bleeding pattern, or there is
40%
vaginal bleeding in a menopausal
woman, there should be an office30%
based endometrial biopsy with a
20%
transvaginal ultrasound. More than
10%
half of women diagnosed with
0%
endometrial cancer are between
90 and over
80-89
70-79
60-69
50-59
40-49
30-39
20-29
the ages of 50-69 as seen in
1%
6%
19%
28%
31%
12%
3%
0%
SCH 2007-2009
Table 4, which compares the age
1%
8%
17%
30%
32%
7%
3%
1%
MN NCDB 2007
of diagnosis of St. Cloud Hospital
1%
9%
18%
30%
28%
10%
3%
0%
Nat’l NCDB 2007
cases with Minnesota and
national cases. Abnormal vaginal
©2010 National Cancer Data Base, Commission on Cancer
bleeding is the most common
symptom, presenting in nine out
of ten women diagnosed. This would include vaginal bleeding or spotting in post-menopausal women and bleeding
between periods in pre-menopausal women. Other symptoms may include pelvic or lower abdominal pain. This
supports women continuing to have regular pelvic exams and pap smears as recommended by their providers.
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TABLE 5

Many endometrial cancers are diagnosed at an
early stage (AJCC 0-I). Of the women diagnosed
and/or treated at St. Cloud Hospital during 2007-09,
50% were diagnosed as stage I. This is consistent
with Minnesota and national findings (Table 5).

Endometrial Cancer: AJCC Stage at Diagnosis
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB)*
60%

% OF CASES

Stage at diagnosis

Treatment

40%
20%
0%

0

I

II

III

IV

1%
50%
17%
9%
5%
Treatment decisions are based on the stage of the
SCH 2007-2009
2%
56%
5%
12%
6%
MN NCDB 2000-2007
tumor. The majority of women with early stage
1%
52%
7%
11%
6%
Nat’l NCDB 2000-2007
endometrial cancer (meaning the cancer has not yet
spread outside of the uterus) will be cured simply
©2010 National Cancer Data Base, Commission on Cancer
by the surgical removal of the uterus. For cases with
more extensive tumors, radiation or radiation and
chemotherapy, in addition to more extensive surgery, are considerations; many require a lymphadenectomy
(removal of surrounding lymph nodes). Recent years have brought changes and eased the way radiation is used to
treat endometrial cancer. In addition, in 2009 St. Cloud Hospital added a surgical oncologist with the ability to treat
more advanced uterine and ovarian cancers.

Since the majority of cases diagnosed and treated
at St. Cloud Hospital are stage I, it is important to look
at the survival rate for this patient group. Observed
five-year survival for stage I patients diagnosed and
treated at St. Cloud Hospital is 96%. This compares
favorably to Minnesota data (91%) and national data
(90%) (Table 6).

19%
23%

Endometrial Cancer: Five Year Observed Survival Rates
Stage 1: 1998 to 2002
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB)
100%
80%
60%
40%
20%
0%

Nathaniel Reuter, MD,
joined the surgical team
at St. Cloud Hospital
in 2009. Dr. Reuter has
received specialized
training for staging
and optimal surgical
management of cancer patients, especially
helpful when treating endometrial and
ovarian cancers.

19%

TABLE 6

CUMULATIVE
SURVIVAL RATE

Survival

NA/Unknown

0.0 yr

1.0 yr

2.0 yr

3.0 yr

4.0 yr

5.0 yr

SCH

100%

100%

MN NCDB

100%

99%

100%

98%

96%

96%

97%

96%

95%

Nat’l NCDB

100%

98%

91%

96%

94%

92%

90%

©2010 National Cancer Data Base, Commission on Cancer
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Ovarian Cancer
Incidence
Ovarian cancer is the ninth most common cancer in women. The American Cancer Society estimates 21,880 new
cases of ovarian cancer will be diagnosed in the United States during 2010. There were 16 women diagnosed and/or
treated for ovarian cancer at St. Cloud Hospital during 2009. This represented 2% of the newly diagnosed cancers
in women seen at St. Cloud Hospital that year. Although ovarian is a relatively rare cancer, receiving a diagnosis of
ovarian cancer is difficult and life-changing.
A significant risk factor for ovarian cancer is age — most ovarian cancers develop after menopause. This is supported
by St. Cloud Hospital, Minnesota and national data shown in Table 7. In the years 2000 to 2007, more than 50%
of ovarian cases were diagnosed at age 60 or older, and greater than 75% were diagnosed at age 50 and older.
Another important risk factor is a strong family history of breast or ovarian cancer. According to the American Cancer
Society, up to 10% of ovarian cancers result from an inherited tendency to develop the disease. Thus, a genetic consult
may be advised for women with an increased familial risk.

Screening
There is currently no effective routine screening for early detection of ovarian cancer. Women who are at high risk
of developing ovarian cancer or have symptoms may be screened/diagnosed with a pelvic exam, transvaginal
ultrasound, a blood test for a tumor marker referred to as CA125 and/or a CT scan. Although these tests are useful in
diagnosing ovarian cancer, they are not currently used for routine screening in asymptomatic or low risk women.
Physicians frequently rely on report of symptoms such as bloating/pelvic pain/change in bleeding pattern and pressure.
Currently, there are research studies looking at the effect of routine screening on mortality. Hopefully in the future
there will be a way to detect ovarian cancer before a woman is symptomatic.

Stage at diagnosis

% OF CASES

Staging of ovarian cancer must be accurate at the time of diagnosis to determine the most effective treatment
and overall prognosis. The primary goal of surgery, usually the first treatment for ovarian cancer, is to obtain tissue
samples for diagnosis and
TABLE 7
staging and to remove as much
cancer tissue as possible.
Ovarian Cancer: Age at Diagnosis
Unfortunately, the majority
St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB): 2000 to 2007
of cases are diagnosed in later
30%
stages, AJCC stage III, followed
by stage IV. Table 8 compares
20%
St. Cloud Hospital’s stage at
10%
diagnosis to similar cancer
0%
programs in Minnesota and
Under 20
20-29
30-39
40-49
50-59
60-69
70-79
80-89
90 and over
nationally. St. Cloud Hospital’s
1%
4%
3%
11%
28%
22%
16%
11%
3%
SCH
breakdown by stage is similar
1%
2%
4%
15%
24%
22%
19%
11%
1%
MN NCDB
1%
2%
4%
14%
23%
23%
21%
12%
1%
to Minnesota data, except for
Nat’l NCDB
©2010 National Cancer Data Base, Commission on Cancer
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TABLE 8

Ovarian Cancer: AJCC Stage at Diagnosis
40%

% OF CASES

stage IV. St. Cloud’s lower percentage may be explained
by the fact that patients with clinically obvious advanced
disease at diagnosis are frequently referred to academic
medical centers. The number of academic referrals is
expected to decrease with the 2009 recruitment of a
surgical oncologist.

St. Cloud Hospital (SCH) and National Cancer Data Base (NCDB)*

30%
20%
10%
0%

Over the past few years, ovarian cancer has been referred
to as the “silent killer” because it usually wasn’t discovered
until it had spread and was in a late stage. New evidence
shows that women with early stage disease may indeed
have symptoms, although subtle. Current efforts are being
made to educate women and providers on the early signs
and symptoms of ovarian cancer to increase detection at
an early stage.

I

II

III

IV

Unknown

N/A

SCH 2007-2009

24%

13%

33%

9%

17%

4%

MN NCDB 2007

21%

10%

27%

20%

22%

1%

Nat’l NCDB 2007

13%

7%

36%

21%

22%

1%

* NCDB data from programs designated as Community Hospital Comprehensive Cancer Programs
by the Commission on Cancer
©2010 National Cancer Data Base, Commission on Cancer

Treatment
Treatment involves surgery and usually chemotherapy. The intent of surgery is to remove as much of the tumor as
possible and is referred to as debulking. Optimal surgical debulking is very important to increase survival. After
recovery from surgery, women diagnosed with ovarian cancer may be referred for chemotherapy. Since 2006, women
with AJCC stage III ovarian cancer may be offered intraperitoneal (IP) chemotherapy along with standard intravenous
chemotherapy. IP chemotherapy infuses anti-cancer drugs directly into the peritoneal cavity (the space that contains the
abdominal organs) through a thin tube. IP chemotherapy requires advanced skill and experience for the surgery and
the chemotherapy administration. IP chemotherapy allows higher doses and more frequent administration of the drugs
and appears to be most effective in killing cancer cells where the ovarian cancer is likely to spread or recur first. Even
though IP chemotherapy has been available at St. Cloud Hospital since 2006, not every woman is a candidate. It is
important to realize that treatment for ovarian cancer requires a multi-disciplinary approach, starting with surgery,
intraperitoneal therapy, when indicated, systemic chemotherapy and sometimes radiation. Even with new research
findings changing the treatment of ovarian cancer, additional studies are needed to further advance screening, early
detection and treatment of this complicated disease. Participation in a clinical trial is always considered when a
patient is diagnosed with ovarian cancer.

Survival
Ovarian cancer causes more deaths than any other cancer of the female reproductive system with an estimated
13,850 deaths projected for 2010 by the American Cancer Society. The high mortality associated with ovarian cancer
is evident when looking at the overall five-year survival rate for all ovarian cases diagnosed from 1998-2002, in
Minnesota (48%) and national (41%), as reported through the National Cancer Data Base. It also is important to note
that the overall five-year survival rate during the same timeframe for AJCC Stage I, in Minnesota (90%) and nationally
(88%), proves that early detection is key to the survival of women with ovarian cancer.
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The St. Cloud Hospital cancer registry
remains busy collecting and reporting
important information about cancer
cases that are diagnosed and/or initially
treated (analytic cases) at St. Cloud
Hospital, Coborn Cancer Center and
Radiation Oncology at Douglas County
Hospital in Alexandria. The information
collected by the cancer registrars
goes beyond the initial cancer
diagnosis and includes a complete
abstract of the patient’s disease from
diagnosis to end of life. Data collected
by the registry is submitted to the
Minnesota Cancer Surveillance System
and the Commission on Cancer’s (CoC’s)
National Cancer Data Base (NCDB).

Submitted by cancer registry

TABLE 9

Analytic Cases by Year
St. Cloud Hospital Cancer Registry
1997 to 2009
1800
1600
1400
1200

# OF CASES

Activity Report

1000
800
600
400
200
0

Actual Cases

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

749

902

973

1219

1198

1343

1251

1404

1378

1470

1613

1498

1561

The registry collected information
YEAR
on 1,561 new cases during 2009
(Table 12). These cases, added to the
17,275 cases already in the registry database, total 18,836 cases that are now followed by the cancer registry.
The current follow-up rate for all living cancer patients entered into the registry data base since 1994 is 95% which
exceeds the CoC’s requirement of 80%. Following patients throughout their life span is vital to understanding the
outcomes of treatment and provides accurate survival information.
The trend in the number of analytic cancer cases has steadily increased (Table 9) over the past 13 years. The most
frequently occurring cancers
TABLE 10
continue to be breast,
prostate, lung, colon/rectum,
AJCC* Stage Group at Diagnosis: 2009 Analytic Cases
malignant lymphoma,
(Total Cases and Top Seven Sites)
with bladder and kidney
AJCC Stage **
following closely (Table 10).
SITE
0
I
II
III
IV UNKNOWN N/A***
Together, these cancers
ALL CASES
168
352
396
191
256
28
170
made up 72% of all
Breast
70
113
73
32
16
2
0
St. Cloud Hospital cases
Prostate
0
0
203
19
13
1
0
in 2009. The ratio of cases
Lung/Bronchus
0
37
17
44
103
2
4
at this facility compares
Colorectal
51
39
23
28
15
2
4
well with the estimated
Malignant Lymphoma 0
28
18
10
33
1
0
cases for Minnesota and the
Bladder
Kidney
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41
1

10
29

5
6

* (AJCC) = American Joint Commission on Cancer
** Collaborative Stage Derived
*** N/A: (Not Applicable): Cancers that do not have an AJCC staging scheme

3
8

5
11

0
1

0
0

TOTAL
1561
306
236
207
162
90
64
56

TABLE 12

United States as published in the American Cancer Society’s
“Cancer Facts and Figures 2009.” (Table 11).
For optimal quality outcomes, lower stage at diagnosis is
desired and results in the availability of more treatment options
and improved survival ratios. Some cancers are easier to screen
for and result in higher percent diagnosis at an earlier stage.
However, due to lack of effective screening methods, early
stage diagnosis is not always possible. This is the case with
lung cancer. The breakdown of stage at diagnosis for the top
seven most frequently diagnosed cancers at St. Cloud Hospital
generally compares to state and national data (Table 10).
An integral role of St. Cloud Hospital cancer registry is to
provide information to monitor quality outcome measures such
as volume, survival, and use of and adherence to clinical
practice guidelines. In addition, the registry provides data
for breast and colorectal cancer quality measures developed
by the CoC. The registry’s data also meets quality standards
(accuracy and timeliness) set by the CoC and the NCDB.
During 2009, the cancer registry achieved an abstracting
timeliness of three and a half months — which well exceeds
the CoC’s requirement of six months — to meet standards
for an accredited cancer program. More than 1,400 cancer
programs submit data to the NCDB, which reflects the
diagnosis and treatment of more than 70% of the newly
diagnosed cancer cases in the United States.
TABLE 11

2009 Incidence of Top Cancer Sites
(Compared to Total Number of Cancer Sites)
St. Cloud Hospital vs Minnesota and Nationwide
25%

% OF CASES

20%
15%
10%
5%
0%

Colorectal**

Non-Hodgkin
Lymphoma

13%

7%

5%

14%

11%

5%

15%

10%

4%

Breast**

Prostate

Lung

St. Cloud Hospital

15%

15%

Minnesota*

14%

21%

Nationwide*

13%

13%

* Minnesota and nationwide statistics taken from the American Cancer Society (ACS) Facts/Figures 2009
** Breast and colorectal numbers include invasive cancers only. The ACS statistics do not provide estimates
for non-invasive breast or colon/rectal cancer.

Site Incidence Data at St. Cloud Hospital
ALL SITES
Head and Neck
Lip and Oral Cavity
Pharynx
Nasal Cavity/Paranasal Sinuses
Salivary Glands
Larynx
Other Head and Neck
Digestive System
Esophagus
Stomach
Colon
Rectum, Rectosigmoid
Anus/Anal Canal
Liver & Bile Ducts
Pancreas
Other Digestive
Respiratory System
Lung/Bronchus
Other Respiratory
Hematopoietic/Lymphoid
Leukemia
Multiple myeloma
Other Hematopoietic
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Bone
Connective Tissue
Skin
Melanoma
Other skin
Breast
Female Genital
Cervix Uteri
Corpus Uteri
Ovary
Vulva
Other
Male Genital
Prostate
Testis
Other Male Genital
Urinary
Bladder
Kidney/Renal pelvis
Other Urinary
Brain and CNS
Brain (Benign)
Brain (Malignant)
Other Brain and CNS
Endocrine
Thyroid
Other
Unknown Primary
Other/Ill-defined Sites
TOTAL

2007
57
19
18
1
10
9
0
276
20
22
126
50
7
7
34
10
232
227
5
146
36
15
25
9
61
4
4
45
44
1
272
42
6
20
16
0
0
302
291
9
2
137
66
68
3
36
1
19
16
41
35
6
20
4
1618

2008
33
11
11
1
2
8
0
266
11
22
139
45
2
6
24
17
185
183
2
159
33
18
29
12
67
2
4
34
32
2
259
51
4
30
14
1
2
248
237
11
0
140
70
66
4
48
1
25
22
50
40
10
24
7
1510

2009
35
6
13
1
4
10
1
253
20
13
111
51
4
7
30
17
210
207
3
157
29
27
11
15
75
0
9
32
31
1
306
55
7
31
16
1
0
254
236
13
5
126
64
56
6
54
2
32
20
46
40
6
19
5
1561
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Components of

a quality cancer program
Measuring the quality of cancer care is much more complicated than it seems at first glance. At Coborn Cancer Center,
we have made diligent efforts to monitor indicators and outcomes, and compare our results to national data. We
compare things like stage at diagnosis, turnaround times, quality of life, best practices, survival rates, etc. These
findings can be viewed by going to www.centracare.com.
Recently there have been news articles and reports about misdiagnoses and erroneous treatment for cancer. How does
a patient find the best and most appropriate place to receive their cancer care?
Things to consider when looking for a quality cancer program:

Comprehensive, state-of-the-art care
Changes in the way cancer is diagnosed, treated and managed
are happening every day. Initiatives in cancer care include
interdisciplinary care (all the specialists collaborating to provide
the best plan); coordinated care, survivorship (follow up and
support during and after treatment); and integration of new
and innovative treatments and procedures. All this requires
a tremendous financial investment and philosophy of
commitment by the organization. Awareness of services to
support state-of-the-art care is a factor to consider in selecting
a cancer care provider.

Volume
Patient volume is another important measure of quality health care. Current literature suggests a high number of cancer
patient visits indicate physicians may be more familiar with, and more practiced at, treating certain types of cancer.
More than 1,550 patients are newly diagnosed or treated at St. Cloud Hospital each year. Most of these patients
receive all of their treatment and follow-up at Coborn Cancer Center. Annually, there are more than 18,000 patient
appointments with providers and greater than 43,000 appointments for services at Coborn Cancer Center.

Research
Research is an important component of comprehensive care. Access to cancer research studies can provide patients
with cutting-edge care options. In addition, participation in research advances cancer care by identifying effective
cancer treatments. More than 50 studies are open for patient enrollment
at any given time at Coborn Cancer Center. Patients are screened for clinical
trial eligibility throughout their cancer care journey. Currently, more than
320 patients are actively being followed while on a cancer research study
at Coborn Cancer Center.
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Location
Most patients prefer to have their care close to home. Diagnosis, treatment
and ongoing follow up for cancer requires frequent visits with the specialist
and long hours receiving tests and treatment at the cancer center. Cancer care
is not provided in isolation by a single provider but is a partnership between
the primary care physician and the cancer specialist (medical and/or radiation
oncologist) and typically supported behind the scenes by numerous specialists
such as surgeons, pathologists, radiologists, geneticists, advanced practice
providers and others with expertise in cancer care. There are more than
400 specialists at St. Cloud Hospital who work together to support patients
and their primary care providers during their cancer journey.

Accreditation, recognition & certification
Coborn Cancer Center has been accredited by the American College of Surgeon’s
Commission on Cancer (CoC) for more than 20 years. The CoC awards accreditation
to programs that provide the best in diagnosis and treatment of cancer. In addition, the Coborn Cancer Center
Radiation department has obtained accreditation status by the American College of Radiology. This accreditation
recognizes quality radiation oncology practices through impartial,
third-party peer review.
Although national certification is not a requirement of employment,
our nurses are committed to providing quality care. This is reflected
through the number of nurses currently holding national certification.
Currently, 63% of the nurses at Coborn Cancer Center hold national
oncology certification.
Thomson Reuters®, a leading health care data company, recognized
St. Cloud Hospital as a Top 100 Hospital for 2009. St. Cloud Hospital
was one of 100 hospitals selected from a final pool of more than
3,000 hospitals nationwide.
Thomson Reuters also honored St. Cloud Hospital with its “Everest
Award for National Benchmarks.” The 23 Everest Award winners have
reached the highest level of accomplishment on the 100 Top Hospitals
national balanced scorecard — balanced performance combined with the fastest rates of long-term improvement.
St. Cloud Hospital is one of only two Minnesota
hospitals to win the Everest Award.
Having obtained Outstanding Achievement as a CoC
certified program, we continually strive for excellence
in cancer care. Should you or your family need cancer
services, we are confident in our ability to provide
the quality and resources you would expect to receive
from the best comprehensive cancer program.

For more information on outcome measures and to look at our
quality reporting for select cancer sites, please visit our Web site at
www.centracare.com/specialty_centers/cancer/quality_measures.html.
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When a community comes together
Casting for a Cure
For Tracy and Joe Schulte, the fight against cancer became a personal affair. Tracy’s mother, Sandy Karasch, lost her
battle to Multiple Myeloma in November 2008. Through their experience, they gained a greater understanding of the
impact cancer has on the patient and their family. Inspired by Sandy’s journey, and the knowledge that three of every
four American families will have at least one family member diagnosed with cancer, the Karasch family created the
Greater Minnesota Fight for a Cure organization.

Multiple myeloma cancer facts:
• More than 20,000 new cases
are diagnosed each year;
• Average age at diagnosis is 70;
and
• Men have a 58 percent higher
incidence rate than women.
— Leukemia Lymphoma Society
Sandy and husband, Rick Karasch,
with their eight grandchildren
(Spring 2007).

Along with a group of dedicated volunteers, they
organized the inaugural “Casting for a Cure,” event —
a fundraiser to raise funds
for cancer awareness,
prevention and resources.
With the help of a very
supportive Central
Minnesota community,
they raised more than
$25,000 for the CentraCare Health Foundation.
Bringing families and community together, they are
making a difference.

Kidney Klimb 2010
Watching your father lose his battle with kidney cancer is no easy feat.
For Jesse Godzala, that experience became the catalyst to make a difference
in the lives of other families. Reflecting on how the experience impacted
his family, and realizing that other families may be experiencing the same
challenges, Jesse set out to do something unique and different — climb
Mount Kilimanjaro to raise awareness and money for kidney cancer.
With the support of individuals and organizations in Central Minnesota,
Jesse, sister Matti, and three others
raised more than $8,500 in
Kidney Klimb’s first year to assist
low-income families with the costs
of medical care. By partnering
with CentraCare Health Foundation
and Coborn Cancer Center,
Kidney Klimb has harnessed the
power of community to support patients and families battling kidney cancer.
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The first Kidney Klimb took place on Mount
Kilimanjaro, Tanzania, Africa.

Kidney cancer facts:
• More than 58,000 new cases
are diagnosed each year;
• Lifetime risk of getting kidney
cancer is about 1 in 70; and
• Men are more likely to be diagnosed
with kidney cancer than women.
— American Cancer Society

Individuals making
a difference

Coborn Cancer Center

Board Members
Hani S. Alkhatib, MD
Hematology/Oncology

Christopher W. Boelter, MD

Cancer is not in a recession — it touches all of us, every day. Last year,
more than 968 individuals gave in excess of $336,875 to support the
cancer funds of the CentraCare Health Foundation and made a difference
in the lives of those who find themselves facing cancer.

Urology

Linda Chmielewski, RN
Vice President, Operations

Shawn K. Day, DO
Family Medicine

Whether it’s helping fund early detection
initiatives, patient education, survivorship
services or care coordinator activities, your
individual gift makes an enormous difference.

Amy Stolt, RN, gastrointestinal care
coordinator, Juli Sanner, RN, OCN, CBCN,
breast care coordinator and Debbie Corrigan,
RN, OCN, lung care coordinator.

Though times are tough, we remain focused
on our vision to become the leader in
Minnesota for quality, safety, service and
value. Your generous support ensures quality
and patient-centered care at every turn.

Marc A. Dvoracek, MD
Pathology

Ronald D. Hanson, MD
Otolaryngology

Mark D. Hauge, MD
Hematology/Oncology

Sandy Johnson, RN, AOCNS
Director, Cancer Community Programs

Donald J. Jurgens, MD
Hematology/Oncology

Barbi L. Kaplan-Frenkel, DO
Medical Director, Radiation Oncology

Maria D. Mallory, MD
Surgery

Cancer Named Funds
Fund-naming opportunities are available for Coborn Cancer Center.
The staff, physicians and patients extend our utmost gratitude.

André L. Mitchell, MD
Radiation Oncology

Paul J. Mitchell, MD
Almeda Ella Pollish Fund
Aunt Leona Fund
Breast Cancer
Greatest Needs Fund
Cancer Survivorship
Network Fund
Carl & Marilyn Savage Fund
Coborn Cancer Center
Endowment Fund
Coborn Cancer Center
Greatest Needs Fund
Craig & Lynn Dahl Fund
Dr. Harold E. Windschitl
Cancer Research Fund

Dr. Nicholas & Bernice Reuter Fund
Greater Minnesota Fight For A Cure Fund
Hank & Dee Coppock Fund
Hind Site Fund
Jean Kershner Lung Cancer Fund
John & Nancy Frobenius
Breast Cancer Fund
Kristine Cunningham Rose
Memorial Fund
Pat Opatz Cancer Research Fund
Pediatric Cancer
Greatest Needs Fund
Quinlivan & Hughes Fund
Surviving with Style Fund

For more information on supporting these funds, or establishing
your own fund, please call CentraCare Health Foundation at
(320) 240-2810. For a complete list of individual benefactors,
please visit www.centracare.com/foundation/benefactors.html.

Surgery

Tracy E. Napp, MD
Radiology

Derek Peterson, RN
Director, Radiation Oncology

Nathaniel P. Reuter, MD
Surgical Oncology

Nicholas F. Reuter, MD
Medical Director, Medical Oncology

Cathy Tieva, RN, OCN
Director, Inpatient Oncology

Jane Vortherms, RN, OCN
Director, Chemotherapy and
Oncology Clinic

Jo Zwilling, RN, MBA
Director, Cancer Program
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Special recognition
Congratulations to Juli Sanner, RN, OCN, CBCN,
breast care coordinator, who recently achieved
national certification and celebrated 11 years of
outstanding service. Juli holds dual national
certifications in oncology nursing and as a
breast care certified nurse.

Juli Sanner, RN, OCN, CBCN, breast care
coordinator.
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Juli is a familiar face representing compassionate,
quality breast cancer care for our community.
Juli assures patients receive timely, coordinated
care based on nationally accepted standards.
In addition, she facilitates support groups,
educates the community and helps raise funds
to improve patient care. We are honored to have
her as a part of our cancer care team.
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